PIM1 and prostate cancer: Treatment with DHPCC-9 significantly slows down migration of both PC-3 prostate cancer cells and UT-SCC-12A squamocellular carcinoma cells, but does not significantly affect metabolic activity or viability of these cells or their levels of Pim expression.